| Literature DB >> 33364418 |
Milou E Noltes1,2, Stephan Brands3, Rudi A J O Dierckx1, Pieter L Jager4, Wendy Kelder5, Adrienne H Brouwers1, Anne Brecht Francken3, Schelto Kruijff2.
Abstract
OBJECTIVE: The aim of this study was to determine the adherence to consensus guidelines on preoperative imaging of patients with primary hyperparathyroidism (pHPT) in real local practice.Entities:
Keywords: adherence; endocrine surgery; guideline; preoperative imaging; primary hyperparathyroidism
Year: 2020 PMID: 33364418 PMCID: PMC7752066 DOI: 10.1002/lio2.464
Source DB: PubMed Journal: Laryngoscope Investig Otolaryngol ISSN: 2378-8038
FIGURE 1Flowchart of patient inclusion. Abbreviations: pHPT, primary hyperparathyroidism; MEN‐1, multiple endocrine neoplasia type 1; MEN‐2A, multiple endocrine neoplasia type 2A; FHH, familial hypocalciuric hypercalcemia
Patients' baseline characteristics
| Characteristics | Criterion adherence (n = 285) | Criterion no adherence (n = 126) | Total (n = 411) |
|
|---|---|---|---|---|
|
Male |
65 (23%) (n = 285) |
31 (25%) (n = 126) |
96 (23%) (n = 411) | .692 |
|
Mean ± SD |
62 ± 13 (n = 285) |
59 ± 13 (n = 126) |
61 ± 13 (n = 411) | .075 |
|
Mean ± SD |
27.3 ± 4.5 (n = 215) |
27.1 ± 4.5 (n = 94) |
27.2 ± 4.5 (n = 309) | .659 |
|
Mean ± SD |
2.89 ± 0.22 (n = 284) |
2.86 ± 0.21 (n = 125) |
2.88 ± 0.22 (n = 409) | .182 |
|
Mean ± SD |
2.83 ± 0.24 (n = 252) |
2.80 ± 0.24 (n = 118) |
2.82 ± 0.24 (n = 370) | .188 |
|
Mean ± SD |
23.4 ± 21.3 (n = 280) |
27.7 ± 44.2 (n = 122) |
24.7 ± 30.1 (n = 402) | .304 |
|
Mean ± SD |
84.05 ± 30.35 (n = 269) |
86.13 ± 32.93 (n = 116) |
84.68 ± 31.12 (n = 385) | .549 |
|
Mean ± SD |
54.92 ± 28.43 (n = 101) |
56.98 ± 25.06 (n = 24) |
55.32 ± 27.73 (n = 125) | .745 |
Note: Criterion adherence = utilization of at least cervical ultrasonography and parathyroid scintigraphy.
Abbreviation: PTH, parathyroid hormone.
Preoperative imaging workup
| Number and combinations of imaging modalities | Criterion adherence, No. (%) | Criterion no adherence, No. (%) | Total, No. (%) |
|---|---|---|---|
| 1. Imaging modality | |||
| PS | 0 | 73 (57.9%) | 73 (17.8%) |
| cUS | 0 | 5 (4.0%) | 5 (1.2%) |
| 18F‐choline PET | 0 | 1 (0.8%) | 1 (0.2%) |
| 2. Imaging modalities | |||
| cUS + PS | 212 (74.4%) | 0 | 212 (51.6%) |
| PS + CT | 0 | 20 (15.9%) | 20 (4.9%) |
| PS + 11C‐methionine PET | 0 | 9 (7.1%) | 9 (2.2%) |
| cUS + 18F‐choline PET | 0 | 4 (3.2%) | 4 (1.0%) |
| PS + 18F‐choline PET | 0 | 2 (1.6%) | 2 (0.5%) |
| cUS + CT | 0 | 1 (0.8%) | 1 (0.2%) |
| PS + 11C‐choline PET | 0 | 1 (0.8%) | 1 (0.2%) |
| 3. Imaging modalities | |||
| cUS + PS + CT | 17 (6.0%) | 0 | 17 (4.1%) |
| cUS + PS + 18F‐choline PET | 13 (4.6%) | 0 | 13 (3.2%) |
| cUS + PS + 11C‐methionine PET | 11 (3.9%) | 0 | 11 (2.7%) |
| cUS + PS + 11C‐choline PET | 7 (2.5%) | 0 | 7 (1.7%) |
| PS + CT + 11C‐methionine PET | 0 | 7 (5.6%) | 7 (1.7%) |
| cUS + PS + 4D‐CT | 4 (1.4%) | 0 | 4 (1.0%) |
| cUS + 4D‐CT + 18F‐choline PET | 0 | 1 (0.8%) | 1 (0.2%) |
| PS + CT + 11C‐choline PET | 0 | 1 (0.8%) | 1 (0.2%) |
| 4. Imaging modalities | |||
| cUS + PS + CT + 11C‐methionine PET | 11 (3.9%) | 0 | 11 (2.7%) |
| cUS + PS + 4D‐CT + 18F‐choline PET | 3 (1.1%) | 0 | 3 (0.7%) |
| cUS + PS + 11C‐methionine PET +11C‐choline PET | 3 (1.1%) | 0 | 3 (0.7%) |
| cUS + PS + CT + 11C‐choline PET | 1 (0.4%) | 0 | 1 (0.2%) |
| PS + CT + 11C‐methionine PET +11C‐choline PET | 1 (0.8%) | 1 (0.2%) | |
| cUS + PS + CT + 18F‐choline PET | 1 (0.4%) | 0 | 1 (0.2%) |
| cUS + PS + 4D‐CT + 11C‐choline PET | 1 (0.4%) | 0 | 1 (0.2%) |
| 5 Imaging modalities | |||
| cUS + PS + 4D‐CT + 11C‐methionine PET + 18F‐choline PET | 1 (0.4%) | 0 | 1 (0.2%) |
| Total | 285 (69.3%) | 126 (30.7%) | 411 (100%) |
Note: Criterion adherence = utilization of at least cervical ultrasonography and parathyroid scintigraphy.
Abbreviations: cUS, cervical ultrasonography; PS, parathyroid scintigraphy 4D‐CT, four‐dimensional computerized tomography.
Procedural characteristics and outcomes stratified by adherence to consensus criteria
| Characteristics | Criterion adherence (n = 285) | Criterion no adherence (n = 126) | Total (n = 411) |
|
|---|---|---|---|---|
|
No. (% per group) | 216 (76%) | 94 (75%) | 310 (75%) | .797 |
|
Mean ± SD |
107 ± 52 (n = 285) |
118 ± 60 (n = 126) |
110 ± 55 (n = 411) | .066 |
|
Mean ± SD |
1646 ± 2621 (n = 259) |
2359 ± 3911 (n = 110) |
1859 ± 3075 (n = 369) | .082 |
|
Mean ± SD |
21.8 ± 20.7 (n = 253) |
23.2 ± 12.3 (n = 115) |
22.3 ± 18.5 (n = 368) | .514 |
|
n (% per group) | 11 (4%) | 4 (3%) | 15 (4%) | .733 |
|
No. (% per group) ≤1 ≥ 2 |
179 (63%) 106 (37%) |
46 (37%) 80 (63%) |
225 (55%) 186 (45%) | <.0005 |
|
postoperative No. (% per group) |
163 (92%) (n = 178) |
80 (91%) (n = 88) |
243 (91%) (n = 266) | .856 |
|
postoperative No. (% per group) |
136 (93%) (n = 147) |
64 (91%) (n = 70) |
200 (92%) (n = 217) | .780 |
|
No. (% per group) | 18 (6%) | 9 (7%) | 27 (7%) | .755 |
|
No. (% per group) | 4 (1%) | 1 (1%) | 5 (1%) | .603 |
Note: Criterion adherence = utilization of at least cervical ultrasonography and parathyroid scintigraphy.
Abbreviations: MIP, minimally invasive parathyroidectomy; POD, postoperative day; HPT, hyperparathyroidism; persistent HPT, failure to achieve normocalcemia within 6 months of parathyroidectomy; recurrent HPT, recurrence of hypercalcemia after a normocalcemic interval > 6 months after parathyroidectomy.
Statically significant.
FIGURE 2Number of patients plotted against the number of imaging procedures combined with the performed surgical approach, also separated for adherence to guidelines (adherence, A, vs no adherence, B). Abbreviations: MIP, minimally invasive parathyroidectomy; BNE, bilateral neck exploration